Pyxis Oncology Inc. - PYXS Net earnings per share for the last four quarters

Official company branding of Pyxis (PYXS)

The Pyxis Oncology, Inc. (PYXS) business model relies on the success of medical tests and sufficient cash reserves to cover development costs. The current market trend on GURU.Markets shows an EPS of 18.80, while the firm depletes its reserves due to a liquidity shortage. Looking ahead, Pyxis Oncology, Inc. (PYXS) plans to generate revenue through the commercialization of unique antibody conjugates for treating severe tumors following the completion of all regulatory clearances.

Pyxis Oncology (PYXS) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/17/2026

PYXS (Pyxis Oncology Inc.): analytical breakdowns and indicator data

Initial company analysis:PYXS, Pyxis Oncology, Inc.
Mass-produced product of Pyxis Oncology

This metric measures the annual change in net income per share over a rolling twelve-month period, reflecting the scaling rate of business profitability. The development of unique antibody-drug conjugates by Pyxis Oncology, Inc. (PYXS) directly impacts the current EPS TTM YoY growth rate through the capitalization of intellectual property. The curve's dynamics allow for an assessment of investment efficiency in precision immuno-oncology. A stable trend confirms the resilience of the company's fundamental value.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months